Serum concentrations of l‐kynurenine predict clinical outcomes of patients with peripheral T‐cell lymphoma, not otherwise specified

• DOI: 10.1002/hon.2318
• Publication Date: 2016-06-25T21:47:52Z
• Authors: Yuhei Shibata; Takeshi Hara; Takuro Matsumoto; Nobuhiko Nakamura; Hiroshi Nakamura; Soranobu Ninomiya; Junichi Kitagawa; Naoe Goto; Yasuhito Nannya; Hiroyasu Ito; Yusuke Kito; Tatsuhiko Miyazaki; Tamotsu Takeuchi; Kuniaki Saito; Mitsuru Seishima; Tsuyoshi Takami; Hisataka Moriwaki; Masahito Shimizu; Hisashi Tsurumi
• Keywords: Indoleamine 2,3-dioxygenase; International Prognostic Index

Abstract Indoleamine 2,3‐dioxygenase exerts intense immunomodulatory effects due to enzymatic activities that catalyze the breakdown of essential amino acid l ‐tryptophan. The activity indoleamine can be estimated by measuring serum ‐kynurenine concentrations. Here, we aimed determine role as a prognostic factor for peripheral T‐cell lymphoma, not otherwise specified (PTCL‐NOS) in retrospective analysis data derived from 31 consecutive patients between June 2000 and March 2013 who were histologically diagnosed with PTCL‐NOS according World Health Organization classification treated 6−8 cycles cyclophosphamide, doxorubicin or pirarubicin, vincristine, prednisolone. concentrations samples collected at admission measured using high‐performance liquid chromatography. median concentration was 3.28 (range 0.92–8.16) μM. cutoff set 3.07 μM receiver operating characteristics curves. complete remission rates <3.07 ≥3.07 69% 51%, respectively. 5‐year overall survival (OS) 80.2% 23.4%, respectively ( p < 0.001). More advanced age, poor performance status, elevated lactate dehydrogenase, an unfavorable International Prognostic Index, index lymphoma significantly worse factors OS. Multivariate analyses revealed only independent In conclusion, might comprise novel which outcomes treatment PTCL‐NOS. Copyright © 2016 John Wiley & Sons, Ltd.